Salivary alpha-1-antitrypsin and macrophage migration inhibitory factor may be potential prognostic biomarkers for oncologic treatment-induced severe oral mucositis - PubMed (original) (raw)

. 2021 Jun;29(6):2939-2946.

doi: 10.1007/s00520-020-05805-2. Epub 2020 Oct 2.

Adriana Franco Paes Leme 2, Tatiane De Rossi 2, Guilherme Pimentel Telles 3, Karina Morais-Faria 4, Luiz Paulo Kowalski 5, Gustavo Nader Marta 6 7, Thaís Bianca Brandão 4 8, Praveen R Arany 9, César Augusto Migliorati 10, Alan Roger Santos-Silva 1, Ana Carolina Prado-Ribeiro 11

Affiliations

Salivary alpha-1-antitrypsin and macrophage migration inhibitory factor may be potential prognostic biomarkers for oncologic treatment-induced severe oral mucositis

Natália Rangel Palmier et al. Support Care Cancer. 2021 Jun.

Abstract

Aims: Evaluate the abundance of the selected targets, alpha-1-antitrypsin (A1AT) and macrophage migration inhibitory factor (MIF), and correlate these findings with the risk of developing severe oral mucositis (OM).

Materials and methods: Head and neck squamous cell carcinoma (HNSCC) patients submitted to radiotherapy (RT) or chemoradiotherapy (CRT) were assessed. OM grade and pain were evaluated daily during treatment. Two protein targets, A1AT and MIF, were evaluated, using selected reaction monitoring-mass spectrometry (SRM-MS), in whole saliva, collected prior to oncologic treatment. The results obtained from the targeted proteomic analysis were correlated with OM clinical outcomes.

Results: A total of 27 patients were included, of whom 21 (77.8%) had locally advanced disease (clinical stage III or IV). Most patients (70.4%) received CRT. OM grades 2 (40.8%) and 3 (33.3%) were the most prevalent during RT with a mean highest reported OM-related pain of 3.22 through the visual analogue scale (VAS). The abundance of A1AT and MIF correlated significantly with severe (grades 3 or 4, p < 0.02) compared with moderate-low (grades 1 or 2, p < 0.04) OM grade.

Conclusions: There is a correlation between the abundance of salivary A1AT and MIF and oncologic treatment-induced OM. The correlation of MIF expression with severe OM appears to be compatible with its physiological pro-inflammatory role. These results open up great possibilities for the use of salivary MIF and A1AT levels as prognostic markers for effective therapeutic interventions, such as photobiomodulation therapy, patient-controlled analgesia, or personalized medicaments.

Keywords: Alpha 1-antitrypsin; Head and neck neoplasms; Macrophage migration inhibitory factors; Oral mucositis; Radiotherapy; Salivary proteins.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Bensadoun RJ, Franquin JC, Ciais G, Darcourt V, Schubert MM, Viot M, Dejou J, Tardieu C, Benezery K, Nguyen TD, Laudoyer Y, Dassonville O, Poissonnet G, Vallicioni J, Thyss A, Hamdi M, Chauvel P, Demard F (1999) Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. Support Care Cancer 7:244–252 - DOI
    1. Gouvêa de Lima A, Villar RC, de Castro G Jr et al (2012) Oral mucositis prevention by low-level laser therapy in head-and-neck cancer patients undergoing concurrent chemoradiotherapy: a phase III randomized study. Int J Radiat Oncol Biol Phys 82:270–275. https://doi.org/10.1016/j.ijrobp.2010.10.012 - DOI - PubMed
    1. Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L (2014) Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 9:e107418. https://doi.org/10.1371/journal.pone.0107418 - DOI - PubMed - PMC
    1. Sonis TS, Hashemi S, Epstein JB, Nair RG, Raber-Durlacher JE (2016) Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol 54:7–14. https://doi.org/10.1016/j.oraloncology.2016.01.005 - DOI - PubMed
    1. Treister N, Sonis S (2007) Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 15:123–129. https://doi.org/10.1097/MOO.0b013e3280523ad6 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources